Boudreau Denise M, Rutter Carolyn M, Buist Diana S M
Group Health Cooperative, Center for Health Studies, Suite 1600, 1730 Minor Avenue, Seattle, WA 98101, USA.
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1026-9. doi: 10.1158/1055-9965.EPI-05-0802.
To evaluate if 3-hydroxy-3-methylglutaryl CoA reductase reductase inhibitor use (statins) alters mammography measured breast density.
Cohort study of women ages 50 to 80 years with two mammography screenings. Changes in BI-RADS breast density between screenings was compared for nonusers, initiators, discontinuers, continuers, and any users of statins.
Statin use was not associated with increases or decreases in breast density compared with nonusers after adjusting for age, body mass index, change in body mass index, hormone therapy use, and time between screenings. Cumulative days of statin use during the year before screening was not associated with changes in breast density in any of the groups of statin users. When hormone therapy users were excluded, any statin use was associated with an increase in breast density compared with nonusers (odds ratio, 1.2; 95% confidence interval, 1.0-1.5).
We found no association between statin use and change in breast density in general, but statin use may be associated with increases in breast density among nonusers of hormone therapy.
评估3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）的使用是否会改变乳腺钼靶检查所测量的乳房密度。
对年龄在50至80岁之间且进行过两次乳腺钼靶筛查的女性进行队列研究。比较了未使用者、开始使用者、停用者、持续使用者以及任何他汀类药物使用者在两次筛查之间BI-RADS乳房密度的变化。
在调整年龄、体重指数、体重指数变化、激素治疗使用情况以及两次筛查之间的时间后，与未使用者相比，他汀类药物的使用与乳房密度的增加或减少无关。在筛查前一年中他汀类药物的累积使用天数与任何他汀类药物使用者组的乳房密度变化均无关。当排除激素治疗使用者后，与未使用者相比，任何他汀类药物的使用都与乳房密度增加有关（优势比，1.2；95%置信区间，1.0 - 1.5）。
我们发现总体上他汀类药物的使用与乳房密度变化之间没有关联，但在未使用激素治疗的人群中，他汀类药物的使用可能与乳房密度增加有关。
